Fox Run Management L.L.C. Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)

Fox Run Management L.L.C. bought a new stake in United Therapeutics Co. (NASDAQ:UTHR) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,216 shares of the biotechnology company’s stock, valued at approximately $429,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Signaturefd LLC increased its stake in United Therapeutics by 4.7% in the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock valued at $234,000 after purchasing an additional 30 shares in the last quarter. Parallel Advisors LLC increased its position in shares of United Therapeutics by 2.8% in the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock valued at $385,000 after buying an additional 30 shares in the last quarter. Great Lakes Advisors LLC raised its stake in shares of United Therapeutics by 1.6% during the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock worth $697,000 after buying an additional 31 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its position in shares of United Therapeutics by 0.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock worth $3,214,000 after buying an additional 33 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its stake in United Therapeutics by 0.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock valued at $1,761,000 after acquiring an additional 39 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In other news, Director Tommy G. Thompson sold 2,500 shares of the business’s stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now owns 8,480 shares in the company, valued at approximately $2,703,424. The trade was a 22.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $929,678.52. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 82,755 shares of company stock valued at $29,792,021. Company insiders own 11.90% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several recent research reports. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. UBS Group upped their target price on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Finally, HC Wainwright reissued a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Price Performance

Shares of UTHR stock opened at $316.73 on Wednesday. The firm’s 50-day simple moving average is $343.28 and its 200-day simple moving average is $356.63. United Therapeutics Co. has a 1-year low of $221.53 and a 1-year high of $417.82. The firm has a market cap of $14.22 billion, a P/E ratio of 13.91, a PEG ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter last year, the business earned $4.36 EPS. Analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.